Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Pfaar, O; Beule, AG; Laudien, M; Stuck, BA, , erweiterte, Leitliniengruppe, ‚Biologika, bei, CRScNP‘.
[Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) with monoclonal antibodies (biologics): S2k guideline of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), and the German College of General Practitioners and Family Physicians (DEGAM)].
HNO. 2023; 71(4): 256-263.
Doi: 10.1007/s00106-023-01273-2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Mitglieder der Med Uni Graz:
- Milger-Kneidinger Katrin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Monoclonal antibodies (so-called biologics) can be prescribed for chronic rhinosinusitis with nasal polyps (CRSwNP) within the scope of their market authorization. However, their prescription is limited to severe CRSwNP without disease control, whereby certain requirements must be met. Dupilumab, omalizumab, and mepolizumab have currently gained market authorization, with adequate evidence for their efficacy and safety available in the literature. It can be assumed that other biologics will be approved for this indication in the future. The severity of disease and the efficacy of treatment should be assessed objectively and subjectively before treatment initiation and after an appropriate duration, respectively. The documentation sheet proposed in this guideline chapter can be used for the assessments. In the presence of relative contraindications, a treatment should only be initiated after differentiated consideration by an experienced physician in the sense of a case-by-case decision. In summary, this guideline chapter aims to contribute to high-quality care of adult patients with these therapies in view of the increasing evidence for treatment with these substances and the increasing number of market authorizations of different biologics.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Humans - administration & dosage
- Antibodies, Monoclonal - therapeutic use
- General Practitioners - administration & dosage
- Physicians, Family - administration & dosage
- Biological Products - therapeutic use
- Nasal Polyps - complications, drug therapy, surgery
- Sinusitis - complications, drug therapy
- Chronic Disease - administration & dosage
- Rhinitis - drug therapy
- Find related publications in this database (Keywords)
- Sinusitis
- Sinunasal diseases
- Asthma
- Nasal polyps